CD40 Antibody (BE-1): sc-65263
- CD40 Antibody (BE-1) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against L cells transfectants expressing CD40 of human origin
- recommended for detection of CD40 of human origin by WB, IP, IF and FCM
- See CD40 (H-10): sc-13128 for CD40 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for CD40 Antibody (BE-1) for WB applications. These reagents are now offered in bundles with CD40 Antibody (BE-1) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD40 Antibody (BE-1) is a mouse monoclonal IgG1 antibody that detects CD40 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD40 is a crucial co-stimulatory receptor found on the surface of B cells, playing a vital role in the activation and proliferation of these immune cells in response to signals from activated T helper cells. The interaction between CD40 and its ligand, CD40L, is essential for initiating a cascade of intracellular signaling that leads to B cell activation, immunoglobulin class switching, and the production of antibodies, including IgE. This process is particularly important for the adaptive immune response, as CD40 enables B cells to produce specific antibodies that target pathogens effectively. Furthermore, CD40 signaling is intricately linked to various post-translational modifications, including ubiquitination, which can influence the stability and activity of CD40, thereby modulating the immune response. Anti-CD40 antibody (BE-1) is an invaluable tool for researchers studying B cell biology and the mechanisms underlying immune responses, providing insights into potential therapeutic targets for immunological disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD40 Antibody (BE-1) References:
- CD40 ligand in CLL pathogenesis and therapy. | Schattner, EJ. 2000. Leuk Lymphoma. 37: 461-72. PMID: 11042507
- CD40 pathway blockade as an approach to immunotherapy. | Burkly, LC. 2001. Adv Exp Med Biol. 489: 135-52. PMID: 11554588
- Prospect of targeting the CD40 pathway for cancer therapy. | Vonderheide, RH. 2007. Clin Cancer Res. 13: 1083-8. PMID: 17317815
- The role of CD40 and CD154/CD40L in dendritic cells. | Ma, DY. and Clark, EA. 2009. Semin Immunol. 21: 265-72. PMID: 19524453
- CD40 Negatively Regulates ATP-TLR4-Activated Inflammasome in Microglia. | Gaikwad, S., et al. 2017. Cell Mol Neurobiol. 37: 351-359. PMID: 26961545
- Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. | Seijkens, TTP., et al. 2018. J Am Coll Cardiol. 71: 527-542. PMID: 29406859
- Engineered fusion protein disrupts CD40 signalling. | Onuora, S. 2019. Nat Rev Rheumatol. 15: 385. PMID: 31168100
- Structural characteristics of CD40 ligand that determine biological function. | Fanslow, WC., et al. 1994. Semin Immunol. 6: 267-78. PMID: 7532457
- CD40 ligand-CD40 interaction in Ig isotype switching in mature and immature human B cells. | Aversa, G., et al. 1994. Semin Immunol. 6: 295-301. PMID: 7532459
- CD40 expression by human fibroblasts. | Fries, KM., et al. 1995. Clin Immunol Immunopathol. 77: 42-51. PMID: 7554483
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD40 Antibody (BE-1) | sc-65263 | 200 µg/ml | $322.00 | |||
CD40 Antibody (BE-1): m-IgG Fc BP-HRP Bundle | sc-539164 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD40 Antibody (BE-1): m-IgG1 BP-HRP Bundle | sc-541304 | 200 µg Ab; 20 µg BP | $361.00 |